EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So!

Image Provided by Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Image Provided by Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Ahmad Doroudian, CEO of BetterLife Pharma Inc. BETR BETRF, was a speaker at Benzinga’s Small Cap Conference in October.

BetterLife an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is focused on developing a portfolio of novel, non-hallucinogenic compounds.

Doroudian discusses BetterLife Pharma’s range of patient-friendly drug candidates and their promising potential for mental health and wellness.

Watch the full presentation:

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.